inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 110.35401/2541-9897-2024-9-4-136-144inovmed-980Research ArticleЛЕКЦИИLECTURESЛегочные осложнения терапевтического лечения онкологических пациентовPulmonary Complications of Cancer Therapyhttps://orcid.org/0000-0002-6845-5613ЗябловаЕ. И.ZyablovaE. I.

Зяблова Елена Игоревна - д. м. н., доцент, заведующая кафедрой лучевой диагностики № 2, КубГМУ; заведующая рентгенологическим отделением, НИИ – ККБ № 1 им. проф. С.В. Очаповского; главный внештатный рентгенолог МЗ Краснодарского края.

350086, Краснодар, ул. Российская 140

Elena I. Zyablova - Dr. Sci. (Med.), Associate Professor, Head of the Diagnostic Radiology Department No. 2, Kuban State Medical University; Head of the Radiology Unit, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Chief Nonstaff Radiologist of the Ministry of Health of the Krasnodar Region.

ulitsa Rossiyskaya 140, Krasnodar, 350086

elenazyablova@inbox.ruhttps://orcid.org/0009-0002-4743-7907КривицкаяЕ. Ю.KrivitskayaE. Yu.

Кривицкая Елена Юрьевна - ассистент кафедры лучевой диагностики № 2, КубГМУ; врач-рентгенолог, НИИ – ККБ № 1 им. проф. С.В. Очаповского.

Краснодар

Elena Yu. Krivitskaya - Assistant Professor at the Diagnostic Radiology Department No. 2, Kuban State Medical University; Radiologist, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1.

Krasnodar

https://orcid.org/0000-0002-0572-2075ВороноваИ. Г.VoronovaI. G.

Воронова Ирина Григорьевна - аспирант кафедры лучевой диагностики № 2, КубГМУ; врач-рентгенолог, НИИ – ККБ № 1 им. проф. С.В. Очаповского.

Краснодар

Irina G. Voronova - Postgraduate Student, Diagnostic Radiology Department No. 2, Kuban State Medical University; Radiologist, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1.

Krasnodar

Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского; Кубанский государственный медицинский университетРоссияScientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical UniversityRussian Federation20243012202404136144Copyright © Зяблова Е.И., Кривицкая Е.Ю., Воронова И.Г., 20242024Зяблова Е.И., Кривицкая Е.Ю., Воронова И.Г.Zyablova E.I., Krivitskaya E.Y., Voronova I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/980

В настоящее время в литературе существует ограниченное количество информации о потенциальных рисках развития легочной токсичности у пациентов с онкологическими заболеваниями, получающих противоопухолевую терапию. Тем не менее у ряда больных данное осложнение встречается довольно часто и может проявляться различными паттернами изменений в паренхиме легких.

Currently, the literature has limited information on potential risks of pulmonary toxicity in patients receiving anticancer therapy. Nevertheless, this complication is not uncommon in some patients and can manifest in various patterns of changes in the lung parenchyma.

легочные осложненияонкологические пациентыпротивоопухолевая терапияpulmonary complicationscancer patientsanticancer therapyReferencesDimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17(3):372–379. PMID: 16291774. https://doi.org/10.1093/annonc/mdj057Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17(3):372–379. PMID: 16291774. https://doi.org/10.1093/annonc/mdj057Dhamija E, Meena P, Ramalingam V, Sahoo R, Rastogi S, Thulkar S. Chemotherapy-induced pulmonary complications in cancer: significance of clinicoradiological correlation. Indian J Radiol Imaging. 2020;30(1):20–26. PMID: 32476746. PMCID: PMC7240883. https://doi.org/10.4103/ijri.IJRI_178_19Dhamija E, Meena P, Ramalingam V, Sahoo R, Rastogi S, Thulkar S. Chemotherapy-induced pulmonary complications in cancer: significance of clinicoradiological correlation. Indian J Radiol Imaging. 2020;30(1):20–26. PMID: 32476746. PMCID: PMC7240883. https://doi.org/10.4103/ijri.IJRI_178_19Nishino M, Hatabu H, Sholl LM, Ramaiya NH. Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care. Radiographics. 2017;37(5):1371–1387. PMID: 28898185. PMCID: PMC5621730. https://doi.org/10.1148/rg.2017170015Nishino M, Hatabu H, Sholl LM, Ramaiya NH. Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care. Radiographics. 2017;37(5):1371–1387. PMID: 28898185. PMCID: PMC5621730. https://doi.org/10.1148/rg.2017170015Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. Published correction appears in N Engl J Med. 2018;379(22):2185. PMID: 25891304. PMCID: PMC5744258. https://doi.org/10.1056/NEJMoa1414428Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. Published correction appears in N Engl J Med. 2018;379(22):2185. PMID: 25891304. PMCID: PMC5744258. https://doi.org/10.1056/NEJMoa1414428Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–1616. PMID: 27540850. https://doi.org/10.1001/jamaoncol.2016.2453Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–1616. PMID: 27540850. https://doi.org/10.1001/jamaoncol.2016.2453Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051– 6060. PMID: 27535979. PMCID: PMC5161686. https://doi.org/10.1158/1078-0432.CCR-16-1320Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051– 6060. PMID: 27535979. PMCID: PMC5161686. https://doi.org/10.1158/1078-0432.CCR-16-1320Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126. Published correction appears in J Clin Oncol. 2022;40(3):315. PMID: 34724392. https://doi.org/10.1200/JCO.21.01440Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126. Published correction appears in J Clin Oncol. 2022;40(3):315. PMID: 34724392. https://doi.org/10.1200/JCO.21.01440Johkoh T, Lee KS, Nishino M, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 2021;298(3):550–566. PMID: 33434111. https://doi.org/10.1148/radiol.2021203427Johkoh T, Lee KS, Nishino M, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 2021;298(3):550–566. PMID: 33434111. https://doi.org/10.1148/radiol.2021203427Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–1192. PMID: 26100356. PMCID: PMC4596761. https://doi.org/10.1158/2326-6066.CIR-15-0102Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–1192. PMID: 26100356. PMCID: PMC4596761. https://doi.org/10.1158/2326-6066.CIR-15-0102Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol. 2013;4(2):231–238. PMID: 23730520. PMCID: PMC3635194. https://doi.org/10.3978/j.issn.2078-6891.2013.008Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol. 2013;4(2):231–238. PMID: 23730520. PMCID: PMC3635194. https://doi.org/10.3978/j.issn.2078-6891.2013.008Souza FF, Smith A, Araujo C, et al. New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging. 2014;14(1):26. PMID: 25608887. PMCID: PMC4331831. https://doi.org/10.1186/1470-7330-14-26Souza FF, Smith A, Araujo C, et al. New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging. 2014;14(1):26. PMID: 25608887. PMCID: PMC4331831. https://doi.org/10.1186/1470-7330-14-26Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122(9):1408–1416. PMID: 26970174. PMCID: PMC5069581. https://doi.org/10.1002/cncr.29961Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122(9):1408–1416. PMID: 26970174. PMCID: PMC5069581. https://doi.org/10.1002/cncr.29961Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–2541. PMID: 16775234. https://doi.org/10.1056/NEJMoa055229Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–2541. PMID: 16775234. https://doi.org/10.1056/NEJMoa055229Diederich S. Chest CT for suspected pulmonary complications of oncologic therapies: how I review and report. Cancer Imaging. 2016;16:7. PMID: 27067027. PMCID: PMC4828781. https://doi.org/10.1186/s40644-016-0066-4Diederich S. Chest CT for suspected pulmonary complications of oncologic therapies: how I review and report. Cancer Imaging. 2016;16:7. PMID: 27067027. PMCID: PMC4828781. https://doi.org/10.1186/s40644-016-0066-4

The authors declare that there are no conflicts of interest present.